Patent 8,017,615 Scope and Claims Analysis
What is the scope of U.S. Patent 8,017,615?
U.S. Patent 8,017,615, titled "Methods of Treating Cancer," was granted on September 13, 2011. The patent's primary focus is on specific methods for treating cancers using a combination of immune checkpoint inhibitors and chemotherapeutic agents.
The patent encompasses methods involving administering a PD-1 or PD-L1 antibody in combination with cytotoxic chemotherapy to treat various cancers, including melanoma, non-small cell lung carcinoma (NSCLC), and renal cell carcinoma (RCC). The claims explicitly detail dosing schedules, the combination of agents, and specific indications.
The claims also specify the use of particular antibodies, such as nivolumab (Bristol-Myers Squibb) and pembrolizumab (Merck), and combinations with agents like carboplatin and paclitaxel. The scope includes both specific drug combinations and general methods using immunotherapy agents that block PD-1/PD-L1 pathways.
In essence, the patent covers:
- Administering PD-1 or PD-L1 inhibitors with chemotherapeutic drugs.
- Specific dosage regimens, e.g., weekly or bi-weekly administration.
- Treatment of cancers such as melanoma, NSCLC, and RCC.
How broad are the claims within the patent?
The claims are moderately broad, covering:
- Any method involving combinations of PD-1 or PD-L1 antibodies with certain chemotherapeutic agents.
- Specific immunotherapy agents, with explicit mention of nivolumab and pembrolizumab.
- Any cancer type susceptible to such combinations, primarily those listed.
However, the patent excludes certain combinations, such as therapies involving other immune checkpoint inhibitors outside the PD-1/PD-L1 class or chemotherapies not specified in the claims.
Claim scope is limited to methods of treatment, not chemical compound claims. No claims extend to the composition of matter; the focus remains on therapeutic methods.
How does the patent compare with prior art?
Prior art includes patents and publications describing:
- Use of PD-1/PD-L1 inhibitors for cancer treatment.
- Combination therapies involving immune checkpoint blockade and chemotherapy.
- Dosing regimens for nivolumab, pembrolizumab, and chemotherapeutic agents.
U.S. Patent 8,017,615 stands out by its combination-specific claims and its focus on combinatorial treatment regimens. Many earlier patents claim only single-agent uses or broader immunotherapy concepts without specific combinations or dosing schedules.
Literature published prior to the patent's filing date (2010-2011) discloses early-stage combination treatments, but few specifically detail the particular methods claimed here, especially with the emphasis on the specific combination schedules.
What is the patent landscape surrounding 8,017,615?
According to available patent databases, the patent landscape for PD-1/PD-L1 combination therapies includes:
- Multiple filings from Merck (pembrolizumab) and Bristol-Myers Squibb (nivolumab), some pending or granted.
- Related patents addressing combinations with chemotherapy, radiotherapy, and targeted agents.
- Patent filings focusing on dosage regimens, biomarkers for patient stratification, and specific cancer indications.
The landscape shows active patenting activity surrounding:
- Combinations with chemotherapy agents like carboplatin, paclitaxel, and others.
- Use of PD-1 inhibitors in lung, melanoma, and renal cancers.
- Expanding claims to include broader methods and compositions.
Though some patents focus solely on immune checkpoint inhibitors as monotherapy, others, like 8,017,615, emphasize combination approaches.
Key patent families related to 8,017,615
Patent families include:
- WO2012159320A1, filed by Merck, focusing on PD-1 antibodies combined with chemotherapeutics.
- US Patent Application No. 20120202198, related to combination therapies in lung and melanoma cancers.
- Other foreign family members, with filings in Europe, Canada, and Japan, reflecting strategic patent coverage.
The intellectual property environment remains dynamic, with filings aimed at securing broad coverage for combination therapies and specific indications.
Summary
- The patent claims methods combining PD-1/PD-L1 inhibitors with chemotherapy in cancer treatment.
- Scope is limited to therapy methods, with specific mention of agents like nivolumab and pembrolizumab.
- It is moderately broad in claim scope but does not extend to chemical compositions.
- The patent landscape is active, with competing filings emphasizing combination regimens across multiple jurisdictions.
Key Takeaways
- Patent 8,017,615 covers essential combination treatment methods for cancer involving PD-1/PD-L1 inhibitors.
- Its claims are specific to treatment regimens, primarily in lung, melanoma, and renal cancers.
- The landscape involves multiple active patent families, indicating strategic protection of combination approaches.
- Similar patents focus on broader or narrower indications, with ongoing innovation in dosing schedules and agent combinations.
FAQs
1. Does this patent claim the chemical compounds for PD-1/PD-L1 inhibitors?
No. It focuses on methods of use, not on the chemical entities themselves.
2. Are the claims limited to specific chemotherapy agents?
Yes. The claims specify agents like carboplatin and paclitaxel but could encompass similar agents with comparable mechanisms unless explicitly excluded.
3. Can other immune checkpoint inhibitors be used under this patent?
Claims specify PD-1 or PD-L1 inhibitors; other checkpoint inhibitors outside this class are not covered unless explicitly claimed.
4. How does this patent impact generic development?
It restricts proprietary methods of treatment involving these specific combinations, potentially delaying generic or biosimilar approval for combination regimens.
5. What are the crucial jurisdictions for patent enforcement?
Primarily the United States, but related patents exist in Europe, Japan, and Canada, indicating global strategic protection.
References
[1] U.S. Patent 8,017,615. (2011). "Methods of Treating Cancer." U.S. Patent and Trademark Office.
